Apomorphine in the treatment of Parkinson's disease

European Neurological Review

Volumn 4, Issue 1, 2009, Pages 28-30

  Katzenschlager, Regina ^a  

^a DANUBE HOSPITAL   (Austria)

Author keywords

Apomorphine; Continuous dopaminergic stimulation; Dyskinesias; Motor complications; Motor fluctuations; Parkinson's disease

Indexed keywords

EID: 84864498616     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2009.04.01.28     Document Type: Article

References (15)

1. Ahlskog JE, Muenter MD, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord, 2001;16:448-58.
2. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinsońs disease: comparison of a patient questionnaire versus a clinician assessment, Mov Disord, 2005;20:726-33.
3. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality, Mov Disord, 1998;13:885-94.
4. Olanow CW, Obeso JA, Stocchi F, Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease, Nat Clin Pract Neurol, 2006;2:382-92.
5. Nilsson D, Nyholm D, Aquilonius SM, Duodenal levodopa infusion in Parkinson's disease-long-term experience, Acta Neurol Scand, 2001;104:343-8.
6. Pahwa R, Koller WC, Trosch RM, Sherry JH, APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose, J Neurol Sci, 2007;258:137-43.
7. Odin P, Apomorphine Injection Therapy for Parkinson's Disease, Akt Neurol, 2005;32:50-55.
8. Deleu D, Hanssens Y, Northway MG, Subcutaneous apomorphine. An evidence-based review of its use in Parkinsońs disease, Drugs Aging, 2004;21:687-709.
9. Colzi A, Turner K, Lees AJ, Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease, J Neurol Neurosurg Psychiatry, 1998;64:573-6.
10. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study, Mov Disord, 2008;23:1130-36.
11. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using singledose challenges, Mov Disord, 2005;20:151-7.
12. Manson AJ, Turner K, Lees AJ, Apomorphine Monotherapy in the treatment of refractory motor complications of Parkinson's Disease-A long-term follow-up study of 64 patients, Mov Disord, 2002;17:1235-41.
13. Alegret M, Valldeoriola F, Marti M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease, Mov Disord, 2004;19:1463-9.
14. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus, J Neurol Neurosurg Psychiatry, 2006;77:450-53.
15. Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years, Arch Gerontol Geriatr Suppl, 2004; (9):291-6.